Literature DB >> 16109199

[Activation of psoriasis in patients undergoing treatment with interferon-beta].

Johan Emdal Navne1, Ulla Hedegaard, Anette Bygum.   

Abstract

Psoriasis is a chronic, inflammatory skin disorder that is induced and aggravated by a number of endogenous and exogenous factors. Traditionally lithium, beta blockers, NSAIDs, ACE inhibitors and antimalarials have been associated with psoriasis, but interferon can also be a triggering factor. We present two patients with multiple sclerosis who suffered from activation of psoriasis in relation to interferon-beta treatment. In one of the patients, psoriasiform injection site lesions persisted six years after termination of the interferon treatment.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16109199

Source DB:  PubMed          Journal:  Ugeskr Laeger        ISSN: 0041-5782


  3 in total

Review 1.  Interferon-β exacerbates Th17-mediated inflammatory disease.

Authors:  Robert C Axtell; Chander Raman; Lawrence Steinman
Journal:  Trends Immunol       Date:  2011-04-29       Impact factor: 16.687

2.  Psoriasis during natalizumab treatment for multiple sclerosis.

Authors:  Jorge Millán-Pascual; Laura Turpín-Fenoll; Pablo Del Saz-Saucedo; Ignacio Rueda-Medina; Santiago Navarro-Muñoz
Journal:  J Neurol       Date:  2012-10-25       Impact factor: 4.849

3.  Psoriasis during interferon beta treatment for multiple sclerosis.

Authors:  Loredana La Mantia; F Capsoni
Journal:  Neurol Sci       Date:  2009-11-19       Impact factor: 3.307

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.